HCPCS Level II code J2779 denotes the injection of ranibizumab via the Susvimo intravitreal implant (0.1 mg). This code captures a novel sustained-release delivery approach for anti-VEGF therapy used in retinal disease management and is important for accurate reporting of device-associated drug administration. Nationally, clear coding of implant-based biologic delivery affects billing consistency, payer coverage determinations, and utilization tracking for high-cost ophthalmic therapies.

Key payers in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on the clinical service represented by the code, the typical settings where the service is delivered, and which payers are commonly involved in coverage. The publication outlines expected benchmarks and policy-relevant details such as payer coverage considerations and coding practice implications for implant-based intravitreal drug delivery.

This summary provides a concise reference for clinicians, billing professionals, and policy analysts seeking to understand how HCPCS Level II code J2779 fits into current ophthalmic therapeutic delivery, payer engagement, and administrative reporting. Data not available in the input is noted where applicable in subsequent sections.